Jump to main content
Jump to site search

Intracellular GSH-responsive camptothecin delivery systems

Author affiliations


Drug delivery systems (DDSs) are invaluable in the scientific field on account of their groundbreaking progress in nanomedicine, which are composed of various nanocarriers, drugs, and the linkers integrating the carriers and drugs. As an effective anticancer medicine, camptothecin (CPT) has been proved to obviously inhibit the cyclic processes of DNA related to replication and transcription through the stable combination with topoisomerase I and DNA. To date, the structural modification of CPT has been carried out at different sites to increase anticancer activity and study the antitumor mechanisms. Nevertheless, due to the hydrophobicity, instability and severe systemic toxicities of CPT, it is feasible to connect nanostructured materials and targeted moieties to CPT, giving rise to advanced smart DDSs whose features and functionality can be tailored to satisfy specific clinical needs. This review describes recent advances in intracellular glutathione (GSH)-controlled DDSs to release CPT. We also emphasize the size, composition and synthesis of the carriers and the linkers between the carriers and CPT, mechanisms of drug release and anticancer efficacies in vitro and in vivo.

Graphical abstract: Intracellular GSH-responsive camptothecin delivery systems

Back to tab navigation

Publication details

The article was received on 08 Oct 2019, accepted on 04 Nov 2019 and first published on 06 Nov 2019

Article type: Paper
DOI: 10.1039/C9NJ05052C
New J. Chem., 2019, Advance Article

  •   Request permissions

    Intracellular GSH-responsive camptothecin delivery systems

    D. Zhang, L. Li, X. Ji and Y. Gao, New J. Chem., 2019, Advance Article , DOI: 10.1039/C9NJ05052C

Search articles by author